Objective: The aim of this study was to investigate the ability of color Doppler ultrasonography to determine prostate cancer, to evaluate the contribution of color Doppler ultrasonography to a conventional greyscale transrectal ultrasonography (TRUS) examination, and to assess the efficacy of prostate-specific antigen (PSA) values in the detection of prostate cancer in combination with sonographic imaging methods.
INTRODUCTION
Prostate cancer is the most common carcinoma in males. [1] The incidence of prostate cancer which is graded according to age was calculated to be 35/100000 in Turkey. [2] As the age increases, the incidence of prostate cancer increases. Therefore, diagnosing prostate cancer and distinguishing it from benign pathologies of the prostate constitute a very important clinical problem.
One of the important steps in the early diagnosis and treatment of prostate cancer is the measurement of prostate specific antigen (PSA) in serum. [3, 4] With the development of defining the disease which is only localized in the prostate gland, curative treatments such as radical prostatectomy and radiotherapy have become possible. Early diagnosis of prostate cancer is also the main purpose of prostatic imaging.
Although the European Urological Association has accepted multiparametric prostate magnetic resonance imaging (MRI) with endorectal coil as the reference method for local staging of prostate cancer, gray scale transrectal ultrasonographic (TRUS) examination with its well-known proven diagnostic value is still considered as a valuable tool. [5] New developments in sonographic technique and many new studies in the literature point to the continuous and dynamic development of this method. With the use of high frequency transducers, new advances have been made in the TRUS examination of prostate cancer. Tissue harmonic imaging, color doppler, power Doppler examinations are well known examples of these developments.
The classical appearance of prostate cancer in TRUS examination is a hypoechoic lesion located in the peripheral zone of the prostate gland. Unfortunately, this finding has low sensitivity and specificity in cancer detection. While only 50% of the hypoechoic areas observed in the peripheral zone of the prostate gland are diagnosed as prostate cancer, [6] 30% of the cancers have been reported to be isoechoic in TRUS. [7] Low positive predictive value of TRUS in the diagnosis of malignant lesions weakens the power of this technique. This makes the biopsy necessary in all peripheral zone lesions. [8, 9] Therefore, the methods to increase the positive predictive value of TRUS are being investigated in order to reduce the cost and morbidity and prevent unnecessary biopsy.
The aim of our study was to investigate the ability of Color Doppler Ultrasound (CDU) in detecting cancer, the contribution of CDU to the TRUS imaging and to evaluate the efficacy of using PSA values together with sonographic imaging methods in detecting prostate cancer.
MATERIALS AND METHODS
The study was performed retrospectively on 78 patients aged between 49-90 years (mean 65.3 years) with a prediagnosis of benign prostate hyperplasia or prostate cancer.
Patients with suspected hypoechogenic lesions on TRUS examination, nodular palpation finding on rectal examination or high PSA (>4 ng/mL) were included in the study. Patients with a diagnosis of prostate cancer who had previously received radiotherapy, surgery, chemotherapy or hormonal therapy, and those with clinically significant cardiovascular disease were excluded from the study.
Diasonic VST master color doppler USG instrument and 7 Mhz transrectal probe were used in the study. B mode ultrasonography (USG) was carefully performed on axial and sagittal planes. In TRUS imaging, the presence and number of the nodules, size, shape, echo structure of the lesion, affected zone, non-mass echo difference in the peripheral zone, loss of peripheral zone and inner gland boundary, capsular invasion, seminal vesicle thickening, prostate seminal vesicle angle obliteration were noted.
The vascularization map was evaluated in sections passing through different areas of the gland. The color flow was graded with a 3-point scale. The findings were compared with the pathology results. CDU examination was performed on the foci which had pathologies in TRUS. In cases without pathology, CDU examination was performed carefully to evaluate diffuse abnormal gland vascularization. The CDU severity of both focal and generalized pathologies were evaluated according to the 0-3 scale as described in the previous publications. [10] Color Doppler flow rating: After B mode and color doppler examination of the prostate gland, the preparation for biopsy was started. After informed consent was obtained, all patients underwent TRUS-guided and systematic biopsies using an 18 gauge (G) tru-cut biopsy set without anesthesia or sedation. Right before the procedure, a single dose of intramuscular (IM) gentamicin was administered for 80 mg and oral ciprofloxacin (2x500 mg) was given for the following 3 days for prophylaxis. One day before the procedure, the fibrous foods were restricted and the rectal cleansing was performed in the morning of the procedure with laxative applied rectally. During the biopsy, it was bewared that a small amount of urine remained in the bladder to limit the cranio-caudal movement of the prostate. Following the le- . While evaluating the study findings, diagnostic tests (specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV)) as well as descriptive statistical methods (mean, Standard deviation, median, frequency, rate) were used. The results were evaluated in 95% confidence interval.
RESULTS
The mean age of our patients was calculated as 65.3 years (49-90 years). The prostate volumes of all cases ranged from 28 to 105 cc with an average of 53.44 cc. According to the biopsy pathology results, a malignancy was detected in 28 cases (36%). All malignant cases were adenocarcinomas with different Gleason scores. The remaining 50 patients (64%) had no malignancy.
In TRUS examination, 36 cases were evaluated as malignant and 42 cases as benign. In our series, the pathology was detected in 51 patients and 27 patients were evaluated as normal in CDU. In laboratory analysis; PSA was suggestive of malignancy (PSA >4.0 ng/mL) in 63 cases and PSA was within normal limits in the remaining 15 cases. 27 patients with PSA values between 4-10 ng/mL were detected. The mean PSAD value of our cases was measured as 0.29. In 45 of the cases, PSAD suggested malignancy (>0.15) and in the remaining 33 cases, PSA were within normal limits.
The distribution of laboratory values and CDU examination findings of the cases by groups are summarized in Table 1 .
28 cases were observed to have color scaled anomaly in CDU examination and to be histopathologically benign. 12 of these patients were diagnosed with benign prostatic hyperplasia (BPH) and 16 were diagnosed with prostatitis. 22 of all malignant cases were evaluated as malignant and 6 were evaluated as benign in TRUS examination.
Complications such as rectal hemorrhage and hematuria after biopsy were negligible.
When the positive predictive value (PPV), negative predictive value (NPV), sensitivity and specificity were calculated for each variable by comparing the results of imaging and laboratory findings with the pathology results in our study, the values in Table 2 were obtained.
If CDU was added to the TRUS for the decision to perform biopsy and the biopsy was not done when CDU was negative, 4 cancer cases (14%) would not be caught. Under this condition, the sensitivity (51%) of TRUS would decrease, and specificity (83%) and NPV (77%) would increase, while the PPV would not change (60%).
DISCUSSION
Accurate, reliable early diagnosis and staging are essential requirements for optimal management of patients with prostate cancer. The most commonly used diagnostic method for the detection of prostate cancer is digital rectal examination (DRE). However, early diagnosis of prostate cancer can be difficult with DRE and various laboratory tests and modern radiological imaging methods are used in addition to DRE in order to prevent delay in di- agnosis. The sensitivity of PSA levels in detecting prostate cancer was found to be better than DRE. However, PSA levels are not specific. [11] [12] [13] This elevation can occur in benign prostatic hypertrophy, acute and chronic prostatitis, prostatic intra-epithelial neoplasia, infarcts, etc. The presence of prostate cancer in people with normal PSA levels makes the situation more complicated and increases the need for imaging methods. [13] Because of the known low sensitivity and specificity of TRUS, which is the most commonly used imaging method in the diagnosis of prostate cancer, additional imaging methods that increase diagnostic power have been investigating for a long time. Advances in sonographic vascular (CDU) imaging help to diagnose prostate cancer. It is known that cancerous tissue initiates a vascular reaction leading to new vascularization. Neovascularization has been reported in many cancers as in prostate cancer. [14] [15] [16] In our study, cancer was detected in 36% by histopathological evaluation. In many studies performed with different imaging methods, the rate of cancer detection was reported to be 29-53%. [17] [18] [19] [20] [21] [22] [23] In our study, sensitivity was higher with color grading (85%) than TRUS (78%), but specificity was lower (TRUS; 72%, CDU 46%). Low specificity is primarily due to the apparent overlap between cancer and prostatitis. As a matter of fact, none of the patients with prostatitis had normal color grading.
The diagnostic strength of TRUS and CDU combination varies between studies. In general, the sensitivity and specificity of combined evaluation have been reported to be between 33-88% and 57-85%. [24] [25] [26] In our study, sensitivity was calculated as 51%, specificity 83%, PPV 60% and NPV 77% when TRUS and CDU were combined. If CDU was added to the TRUS for the decision to perform a biopsy and the biopsy was not performed when CDU was negative, 4 cancer cases (14%) would not be caught. Our results are similar to the studies evaluating the information in the literature on a case-by-case basis, whereas more satisfactory results were obtained in studies that evaluated CDU separately for each biopsy area. In a study of this type, they reported 93% specificity. [27] Kelly et al. [28] found higher positive predictive values compared to CDU by doing TRUS alone. In our study, the positive predictive value of TRUS (61%) was higher than the color grading (47%).
Kelly et al. reported 1 case of CDU that could not be visualized by conventional gray scale USG to represent 1.3% of all patients in the study. Rifkin et al., [29] in a study where they did with a bigger group, identified abnormal color flow normal gray scale in 9 of 132 cancer cases (7%) and in 5% of benign lesions. Abnormal color flow monitoring is a rare condition although TRUS evaluation is normal. This may indicate both benign and malignant conditions. In our series, there was only one case with abnormal color flow and a normal gray scale. Unfortunately, despite the inclusion of CDU findings, it remains difficult to diagnose the isoechoic prostate cancers.
Should the decrease in vascularity be evaluated for benignity? We cannot respond positively to this question since we have seen cases detected with cancer despite of being "CDU negative". Numerous cases of CDU-negative cancer have been reported in the literature, as well. With the available data, we cannot reveal a possible link between Gleason stage and CDU. In a study by Newman et al. [27] that correlated CDU with histological results in all biopsy sites, no correlation could be established between the Gleason score and CDU.
It is well known that ultrasonography, a subjective examination method, depends on the experience of the examiner. Although it cannot be clearly demonstrated in this study, it can be argued that CDU examination may eliminate the experience dependent situation.
Screening for prostate cancer is based on a triad of DRE, PSA and TRUS. Many studies have demonstrated that the combined use of these three studies facilitates cancer detection. [30, 31] In our study, when TRUS + CDU + PSAD were used together, the sensitivity was 64.28% and the specificity was 80%.
Due to the low specificity of TRUS-guided prostate biopsy in hypoechoic nodules originating from the peripheral region, not only biopsy of nodules but systematic biopsy is required. Combining random and targeted biopsies with or without palpable abnormalities increases the rate of cancer detection. Our results suggest that combined sensitivity calculated from CDU and TRUS may not be sufficient to prevent random biopsies.
The sensitivity and specificity of prostate MRI imaging, which is a popular imaging modality recently, in the detection of prostate cancer were reviewed with three meta-analysis. In the one with 21 studies using Prostate imaging reporting and data system (PIRADS version 2) V2, 89% of common sensitivity and 73% of specificity were calculated. [32] Compared to multiparametric prostate MRI meta-analysis [33] that did not use prostate imaging reporting and data system (PIRADS) and PIRADS V1, [34] PIRADS V2 studies showed increased sensitivity while specificity decreased slightly (sensitivity and specificity values for both studies were 74% and 88%, [33] 78% and 79% [34] respectively). In a meta-analysis consisting of 16 studies and 2624 patients, the sensitivity and specificity of ultrasound using contrast material for detecting prostate cancer were determined as 70% and 74%, respectively. [35] When the sensitivity and specificity of the triple combination (64.28% and 80%), which we obtained the best results in our study, were compared with the results of prostate MRI and prostate ultrasound with contrast; the specificity values of our study were comparable with the new techniques, but the sensitivity values were lower.
The main limitation of our study is that the grading of vascularization depends on the subjective evaluation of the person who applies the CDU. Other limitations include the relatively small number of cases, the absence of rectal examination findings in the study, the fact that CDU was not recorded separately for each biopsy site, no correlation of Gleason score, and the absence of new sonographic applications such as USG with contrast or elastography.
After all; in our study, the addition of CDU to TRUS increased the specificity but decreased the sensitivity (from 78% to 51%). CDU examination findings can be considered as one of the secondary findings (e.g. loss of normal accepted limits, bulging at the contour) used to make a biopsy decision for cancer diagnosis. According to our results, although we cannot claim that CDU provides a significant advantage in the diagnosis of cancer, color flow grading better identifies the prospective biopsy sites. Because of the low specificity of Color Doppler examination, it should be evaluated with Gray Scale and PSA findings. As a matter of fact, we obtained the best specificity (80%) by using three methods together. Although the specificity obtained by using three methods together was similar to new techniques such as multiparametric prostate MRI and prostate USG examination with contrast, the sensitivity values were lower.
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